<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>默克（Merck KGaA）在德国交易中股价上涨约 8%，因为该科技巨头周三上调了 2026 财年的指引，并维持了中期展望，尽管第一季度业绩疲软。</p>
<p>展望 2026 财年，默克现在预计净销售额将在 204 亿欧元至 214 亿欧元之间，EBITDA 预期在 57 亿欧元至 61 亿欧元之间。</p>
<p>默克之前预计净销售额在 200 亿欧元至 211 亿欧元之间，EBITDA 预期在 55 亿欧元至 60 亿欧元之间。</p>
<p>每股收益预期现在在 7.50 欧元至 8.20 欧元之间，高于之前的 7.10 欧元至 8.00 欧元的估计范围。</p>
<p>该公司表示，此次修订主要反映了生命科学领域更强劲的势头和医疗保健在挑战环境中的韧性假设。</p>
<p>该指引现在假设自 2026 年 5 月起在美国不再销售 Mavenclad，而之前的预测是从 2026 年 3 月开始，因面临仿制药竞争，并排除了在美国商业化 Pergoveris 的潜在可能性。</p>
<p>在有机基础上，集团净销售额将持平或增长 3%，EBITDA 预期将同比下降 2% 至增长 2%。</p>
<p>之前，该公司预计有机净销售额发展将下降 1% 至增长 2%，有机 EBITDA 预期发展将下降 4% 至增长 1%。</p>
<p>此外，默克确认了之前的中期指引，并继续目标为年均有机销售增长在中个位数百分比范围内。对于 EBITDA 预期利润率，该公司认为有潜力提升至约 30%。</p>
<p>在第一季度，默克 KGaA 归属于股东的净收入总计为 6.59 亿欧元，每股 1.52 欧元，而去年为 7.35 亿欧元，每股 1.69 欧元。</p>
<p>每股收益预期为 2.11 欧元，而去年为 2.12 欧元。</p>
<p>EBITDA 预期从去年的 15.35 亿欧元微降 0.3% 至 15.30 亿欧元。有机 EBITDA 预期增长 5.3%。EBITDA 预期利润率从去年的 29.1% 提高至 29.8%，得益于电子业务部门的一次性效应。</p>
<p>该公司在此期间的净销售额从去年的 52.80 亿欧元下降 2.8% 至 51.34 亿欧元。有机收入增长为 2.9%，主要受过程解决方案和半导体材料部门的推动。</p>
<p>在德国 XETRA 市场，默克 KGaA 的股票交易价格为 121.70 欧元，上涨 7.7%。</p>
<p>有关更多收益新闻、收益日历和股票收益，请访问 rttnews.com。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

德国默克

默克(ADR)

<p>默克（Merck KGaA）的股价在公司尽管第一季度业绩疲软但仍提高了 2026 财年的指引后上涨了约 8%。新的预测预计净销售额为 204 亿至 214 亿欧元，EBITDA 前景为 57 亿至 61 亿欧元，均高于之前的预估。公司确认了其中期指引，目标是年均有机销售增长在中个位数范围内。在第一季度，净收入降至 6.59 亿欧元，净销售额下降 2.8% 至 51.34 亿欧元。该股票在 XETRA 交易所的交易价格为 121.70 欧元，反映出 7.7% 的涨幅</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Shares of Merck KGaA were gaining around 8 percent in German trading after the science and technology major on Wednesday lifted its fiscal 2026 guidance and maintained mid-term view, despite weak first-quarter results.</p>
<div class="lb-trans"><p>默克（Merck KGaA）在德国交易中股价上涨约 8%，因为该科技巨头周三上调了 2026 财年的指引，并维持了中期展望，尽管第一季度业绩疲软。</p>
</div><p>Looking ahead for fiscal 2006, Merck now anticipates net sales between 20.4 billion euros and 21.4 billion euros, and EBITDA pre between 5.7 billion euros and 6.1 billion euros.</p>
<div class="lb-trans"><p>展望 2026 财年，默克现在预计净销售额将在 204 亿欧元至 214 亿欧元之间，EBITDA 预期在 57 亿欧元至 61 亿欧元之间。</p>
</div><p>Merck previously projected net sales between 20.0 billion euros and 21.1 billion euros, and EBITDA pre between 5.5 billion euros and 6.0 billion euros.</p>
<div class="lb-trans"><p>默克之前预计净销售额在 200 亿欧元至 211 亿欧元之间，EBITDA 预期在 55 亿欧元至 60 亿欧元之间。</p>
</div><p>Earnings per share pre is now projected between 7.50 euros and 8.20 euros, higher than previous estimate in a range of 7.10 euros to 8.00 euros.</p>
<div class="lb-trans"><p>每股收益预期现在在 7.50 欧元至 8.20 欧元之间，高于之前的 7.10 欧元至 8.00 欧元的估计范围。</p>
</div><p>The company said the revision primarily reflects assumptions of stronger momentum in Life Science and Healthcare's resilience in a challenging environment.</p>
<div class="lb-trans"><p>该公司表示，此次修订主要反映了生命科学领域更强劲的势头和医疗保健在挑战环境中的韧性假设。</p>
</div><p>The guidance now assumes no sales of Mavenclad in the United Sates from May 2026, while previous forecast was from March 2026, amid generic competition, and excludes the potential commercialization of Pergoveris in the United States.</p>
<div class="lb-trans"><p>该指引现在假设自 2026 年 5 月起在美国不再销售 Mavenclad，而之前的预测是从 2026 年 3 月开始，因面临仿制药竞争，并排除了在美国商业化 Pergoveris 的潜在可能性。</p>
</div><p>On an organic basis, group net sales would be flat to up 3 percent, and EBITDA pre would be down 2 percent to up 2 percent year-over-year.</p>
<div class="lb-trans"><p>在有机基础上，集团净销售额将持平或增长 3%，EBITDA 预期将同比下降 2% 至增长 2%。</p>
</div><p>Previously, the company projected that organic net sales development would be down 1 percent to up 2 percent and organic EBITDA pre development would be down 4 percent to up 1 percent.</p>
<div class="lb-trans"><p>之前，该公司预计有机净销售额发展将下降 1% 至增长 2%，有机 EBITDA 预期发展将下降 4% 至增长 1%。</p>
</div><p>Further, Merck confirmed its previous mid-term guidance, and continues to target annual organic sales growth in the mid-single-digit percentage range. For the EBITDA pre margin, the company sees potential for a step-up to approximately 30 percent.</p>
<div class="lb-trans"><p>此外，默克确认了之前的中期指引，并继续目标为年均有机销售增长在中个位数百分比范围内。对于 EBITDA 预期利润率，该公司认为有潜力提升至约 30%。</p>
</div><p>In the first quarter, Merck KgaA's net income attributable to shareholders totaled 659 million euros or 1.52 euros per share, compared with 735 million euros or 1.69 euros per share last year.</p>
<div class="lb-trans"><p>在第一季度，默克 KGaA 归属于股东的净收入总计为 6.59 亿欧元，每股 1.52 欧元，而去年为 7.35 亿欧元，每股 1.69 欧元。</p>
</div><p>Earnings per share pre came in at 2.11 euros, compared to last year's 2.12 euros.</p>
<div class="lb-trans"><p>每股收益预期为 2.11 欧元，而去年为 2.12 欧元。</p>
</div><p>EBITDA pre edged down 0.3 percent to 1.530 billion euros from 1.535 billion euros last year. EBITDA pre grew 5.3 percent organically. EBITDA pre margin of 29.8 percent improved from 29.1 percent a year ago, supported by one-time effects in the Electronics business sector.</p>
<div class="lb-trans"><p>EBITDA 预期从去年的 15.35 亿欧元微降 0.3% 至 15.30 亿欧元。有机 EBITDA 预期增长 5.3%。EBITDA 预期利润率从去年的 29.1% 提高至 29.8%，得益于电子业务部门的一次性效应。</p>
</div><p>The company's net sales for the period fell 2.8 percent to 5.134 billion euros from 5.280 billion euros last year. Organic revenue growth was 2.9 percent, driven by Process Solutions and Semiconductor Materials segments.</p>
<div class="lb-trans"><p>该公司在此期间的净销售额从去年的 52.80 亿欧元下降 2.8% 至 51.34 亿欧元。有机收入增长为 2.9%，主要受过程解决方案和半导体材料部门的推动。</p>
</div><p>On the XETRA in Germany, Merck KGaA shares were trading at 121.70 euros, up 7.7 percent.</p>
<div class="lb-trans"><p>在德国 XETRA 市场，默克 KGaA 的股票交易价格为 121.70 欧元，上涨 7.7%。</p>
</div><p>For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.</p>
<div class="lb-trans"><p>有关更多收益新闻、收益日历和股票收益，请访问 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

尽管第一季度表现疲软，德国默克仍提升了 2026 财年的展望，并支持积极的中期观点；股价上涨